TNF and inflammatory bowel disease: For example, even with first-line of defense, biologics such as anti-tumor necrosis factors (TNFs), it is estimated that 10–40% of IBD patients do not respond to primary treatment [17,18] and almost 50% will stop responding over time [19,20].